A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer (“NK”) cell therapy is already legal. NKGen proposal included up to $18 million in ...

The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.

Innate Pharma's IPH6501, highlighted in Science Immunology, shows potential in next-gen cancer therapy, targeting B-NHL with ...

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared ...

Severe infection with Covid-19 has been found to produce a powerful cancer-fighting cell that can shrink tumors.

Hidradenitis suppurativa, commonly referred to as HS, is a debilitating skin condition that causes chronic inflammation on ...

Fate Therapeutics' FT522 explores treatments for lymphoma and autoimmune disorders. Read why FATE stock remains a top pick in ...

CAR-T Cells: As the largest class in adoptive cell therapy, CAR-T cells are being engineered for greater precision, reduced toxicity, and durable anti-tumor responses. Advancements aim to address ...

Senti Bio (SNTI)science reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential ...

Lacutamab is granted orphan drug status in the European Union and in the United States for the treatment of CTCL ... of ...